Viatris Inc (VTRS) Stock Price, Quote & News

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 724 514 1800

Website: www.viatris.com

Address:

Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States

SuperGreenToday Oct. 4 at 1:33 AM

$VTRS Share Price: $10.19 Contract Selected: Apr 17, 2026 $10 Calls Buy Zone: $0.94 – $1.16 Target Zone: $1.76 – $2.15 Potential Upside: 78% ROI Time to Expiration: 195 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

MoneyGroupLLC Oct. 3 at 10:14 PM

Enter: $VTRS NOV 21 2025 $11 CALLS Buy in Price: $0.24 - $0.25 Take Profit: $0.36 Stop Bleeding: $0.21 ROI Potential: 48% Exit Within: 295 Minutes https://moneygroup.us/alerts

0 · Reply

SniperPro Oct. 3 at 2:34 PM

$LXRX $NVO $BMY $VTRS $PFE We’ve got so many positive catalysts ahead! Don’t forget: SOTA USA/EU partner LX9211 partner And who knows what other molecules they’re negotiating behind the scenes—only God knows. The NVO deal came out of nowhere; even I was caught by surprise. At this point, shorting this low is a risky move—anything can happen. MAHA + FDA are not messing around, and this administration knows too many good drugs have been left on the back burner for far too long. 💥 The tide is turning.

1 · Reply

SPYmyQQQ Oct. 2 at 7:23 PM

🏛️ 🚀 $VTRS up ⬆️6.93% since our entry $9.52 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!

0 · Reply

ShirleyG Oct. 2 at 6:03 AM

$VTRS let's goooo!!!! $12🚀📈

0 · Reply

SPYmyQQQ Oct. 1 at 5:01 PM

🏛️ 🚀 $VTRS up ⬆️6.83% since our entry $9.52 on Sep 26, 2025 👉 FREE TRIAL! Check bio. ALL signals Time stamped. NO B.S.!

0 · Reply

SniperPro Oct. 1 at 4:43 PM

$VTRS $NVO $BMY $LXRX $PFE acquired Arna for $100 per share, and they didn't even have one-third of Lex's assets or the Genome5000 platform—so your calculations are significantly off... Ray knows what he owns... Sota alone, in the right hands and with the right marketing team, has the potential to generate billions of dollars in future revenue. ...

2 · Reply

mdes Oct. 1 at 4:02 PM

$KVUE $VTRS CHC spinoffs need to consider M&A for synergies and growth .. I guess there are many other similar spinoff

0 · Reply

SPYmyQQQ Oct. 1 at 2:07 PM

🎯 Target Hit 🏁 📨 Signal From Sep 17, 2025 🏛️ $VTRS 💵 Entry: $9.7400 ✅ Exit: $10.1053 💰 P/L: +3.75% 👉 Free Trial! Check bio.

0 · Reply

SniperPro Sep. 30 at 10:38 PM

$PFE $BMY $LXRX $NVO $VTRS I wouldn’t be surprised if they soon announce a partner for a brand-new molecule. As CEO Mike Exton has stated, Lexicon now has three or more candidates ready from lab work. With the Genome5000 program fueling target discovery, the upside someday could be huge — we’re living in exciting times. LFG

0 · Reply

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 25, 2025, 1:16 PM EDT - 9 days ago

Viatris: Indore Plant Could Boost 2026 Numbers

Aug 19, 2025, 9:00 AM EDT - 6 weeks ago

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Aug 15, 2025, 1:34 PM EDT - 7 weeks ago

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

AMCR ARE BMY BXP CAG CPB CVX

Aug 11, 2025, 9:29 AM EDT - 7 weeks ago

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Aug 7, 2025, 11:02 AM EDT - 2 months ago

Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 9:36 AM EDT - 2 months ago

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Aug 7, 2025, 6:59 AM EDT - 2 months ago

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Aug 5, 2025, 6:59 AM EDT - 2 months ago

Viatris Announces Quarterly Dividend

Aug 5, 2025, 6:55 AM EDT - 2 months ago

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Aug 1, 2025, 10:00 AM EDT - 2 months ago

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Jul 22, 2025, 11:19 AM EDT - 2 months ago

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

CIVI CMCSA CRGY CWEN KSS LNC NXST

Jul 18, 2025, 2:17 PM EDT - 2 months ago

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Jul 18, 2025, 8:47 AM EDT - 2 months ago

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Jul 18, 2025, 7:07 AM EDT - 2 months ago

Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 6:59 AM EDT - 2 months ago

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Jul 16, 2025, 3:19 AM EDT - 2 months ago

Viatris: A Contrarian Bet With Virtually No Downside

Jul 11, 2025, 5:23 PM EDT - 3 months ago

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

AES AMCR ARE BMY CAG CPB CVX

Jun 26, 2025, 6:55 AM EDT - 3 months ago

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Jun 12, 2025, 4:30 PM EDT - 4 months ago

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 9, 2025, 1:06 PM EDT - 4 months ago

Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 5, 2025, 11:04 AM EDT - 4 months ago

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript

Jun 2, 2025, 1:12 PM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

$Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions$

Jun 2, 2025, 8:00 AM EDT - 4 months ago

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

May 31, 2025, 8:45 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

May 31, 2025, 7:07 AM EDT - 4 months ago

VTRS CLASS NOTICE: Viatris Inc. Investors may have been Affected by Fraud – Contact BFA Law before June 3 Court Deadline (NASDAQ:VTRS)

May 30, 2025, 9:06 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Berger Montague Reminds Viatris (NASDAQ: VTRS) Investors of the June 3, 2025 Deadline

May 27, 2025, 10:38 AM EDT - 4 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors to Contact the Firm Before June 3, 2025

May 25, 2025, 7:42 AM EDT - 4 months ago

VTRS FRAUD: Suffer Losses on Viatris Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:VTRS)

May 23, 2025, 3:18 PM EDT - 4 months ago

VTRS FRAUD NEWS: Viatris Inc. is Being Sued for Securities Fraud; Investors That Lost Money Are Urged to Contact BFA Law by June 3 Court Deadline

May 22, 2025, 6:59 AM EDT - 4 months ago

Viatris to Participate in Upcoming Investor Conferences

May 21, 2025, 1:18 PM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Lawsuit – VTRS

May 21, 2025, 8:46 AM EDT - 4 months ago

VTRS LAWSUIT: Lose Money on Viatris Inc.? Contact BFA Law before June 3 Court Deadline

SuperGreenToday Oct. 4 at 1:33 AM

0 · Reply

MoneyGroupLLC Oct. 3 at 10:14 PM

Enter: $VTRS NOV 21 2025 $11 CALLS Buy in Price: $0.24 - $0.25 Take Profit: $0.36 Stop Bleeding: $0.21 ROI Potential: 48% Exit Within: 295 Minutes https://moneygroup.us/alerts

0 · Reply

SniperPro Oct. 3 at 2:34 PM

1 · Reply

SPYmyQQQ Oct. 2 at 7:23 PM

🏛️ 🚀 $VTRS up ⬆️6.93% since our entry $9.52 on Sep 26, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!

0 · Reply

ShirleyG Oct. 2 at 6:03 AM

$VTRS let's goooo!!!! $12🚀📈

0 · Reply

SPYmyQQQ Oct. 1 at 5:01 PM

🏛️ 🚀 $VTRS up ⬆️6.83% since our entry $9.52 on Sep 26, 2025 👉 FREE TRIAL! Check bio. ALL signals Time stamped. NO B.S.!

0 · Reply

SniperPro Oct. 1 at 4:43 PM

2 · Reply

mdes Oct. 1 at 4:02 PM

$KVUE $VTRS CHC spinoffs need to consider M&A for synergies and growth .. I guess there are many other similar spinoff

0 · Reply

SPYmyQQQ Oct. 1 at 2:07 PM

🎯 Target Hit 🏁 📨 Signal From Sep 17, 2025 🏛️ $VTRS 💵 Entry: $9.7400 ✅ Exit: $10.1053 💰 P/L: +3.75% 👉 Free Trial! Check bio.

0 · Reply

SniperPro Sep. 30 at 10:38 PM

0 · Reply

SPYmyQQQ Sep. 30 at 7:28 PM

🎯 Target Hit 🏁 📨 Signal From Sep 26, 2025 🏛️ $VTRS 💵 Entry: $9.5200 ✅ Exit: $9.8570 💰 P/L: +3.54% 👉 Check bio for full access

0 · Reply

highnihilism Sep. 30 at 10:22 AM

$VTRS Viatris: 82 trades, $37K vs $112K avg (0.33x !!). $34K calls / $3K puts. $FSS Federal Signal: 10 trades, $35K vs $23K avg (1.49x). $34K calls / $1K puts. $OLN Olin: 126 trades, $49K vs $219K avg (0.22x !!). $34K calls / $15K puts. $LH Labcorp: 22 trades, $178K vs $167K avg (1.06x). $34K calls / $144K puts.

0 · Reply

ShirleyG Sep. 27 at 6:37 PM

$VTRS $12🚀

1 · Reply

SPYmyQQQ Sep. 27 at 12:01 AM

🌙 EOD Recap ✅ $VTRS 🗓️ Sep 26, 2025 (8pm ET) 💵 Our Entry: $9.5200 🎯 Target (Opt.): $9.8570 (+3.54%) 👉 Check bio for full access

0 · Reply

SniperPro Sep. 26 at 11:33 PM

$LXRX @Jbjb90 @Softclothes $BMY Pilavapadin ? You’re both starting to understand why BlackRock, Vanguard, and State Street—along with Artal/Invus—own the majority of this company. Our little baby pharma has long been suppressed by big pharma players. But once $NVO and $VTRS took us under their wing, things finally started moving in the right direction. Those who tried to crush this rising queen will eventually be left eating dirt. Most investors don’t take the time to truly research what they’re getting into. They just buy and hope for the best. But when you dig deep, ask the right questions, and understand a company’s future revenue potential—that’s when your modest investments can turn into golden tickets. Research $BMY Pilavapadin connection, research and co-development... potential partner... Big BOOM!! Don’t let some clueless schmuck steer you off course. Stay focused. Good luck!

2 · Reply

SPYmyQQQ Sep. 26 at 3:33 PM

🚀 New Signal ✅ 🏛️ $VTRS 🗓️ Sep 26, 2025 💵 Entry: $9.52 🎯 Target (Opt.): $9.86 (+3.54%) 👉 Check bio for full access

0 · Reply

MoneyGroupLLC Sep. 25 at 11:39 PM

Enter: $VTRS OCT 17 2025 $10 CALLS Buy in Price: $0.20 - $0.20 Take Profit: $0.48 Stop Bleeding: $0.18 ROI Potential: 140% Exit Within: 215 Minutes https://moneygroup.us/alerts

0 · Reply

SniperPro Sep. 25 at 8:35 PM

$LXRX $VTRS is the most successful distributor in Asia, so expect them to move fast and start selling Inpefa this year — Viatris doesn’t mess around! Just like $NVO, they control over 70% of global obesity and entering cardiometabolic market sales... We don’t need a bunch of partners — just the right ones who can drive sales beyond any competitor. Fun Fact: As of September 2025, the continent of Asia has a population of approximately 4.84 billion people. lfg

3 · Reply

SniperPro Sep. 25 at 6:15 PM

$LXRX The Future Has Never Been Brighter Than Today!!! Today, we’re in a fundamentally different position: FDA Approvals Secured INPEFA® approved for heart failure — a massive and growing market. ✅ Two Major Commercial Partnerships $NVO $VTRS With global sales leaders to scale commercialization and distribution. $1.3B+ in Potential Deal Value Secured through milestone payments and unlimited royalties spanning multiple years. ✅ Two Additional Billion-Dollar Deals in the Pipeline With ongoing discussions and indications of value creation beyond current deals. $BMY $PFE ? ✅ The Disconnect Despite these advancements, the stock is currently trading significantly below its 2024 highs $3.73 — when it had no pipeline execution and no financial foundation. ✅ Today’s Lexicon is backed by: FDA-validated science Commercial traction through partnerships A cash runway and capital access Billion-dollar upside from royalties and pipeline value. It’s crazy— Let this sink in…

1 · Reply

SniperPro Sep. 23 at 7:10 PM

🚀💪🏻⏰📡⏰ $LXRX $BMY $NVO $VTRS $PFE Enough is enough with Powell dragging down the markets. If you or anyone you know has a way to reach him, please pass along a respectful message.... (1) Not everyone who shits on you is your enemy. (2) Not everyone who gets you out of shit is your friend. (3) And when you’re in deep shit, it’s best to keep your mouth shut! ☠️🤣

2 · Reply

HarveyToronto Sep. 23 at 6:15 PM

$KDP calls 25c — aiming to earn my drinks money 🍹 $BA 220–240 call spread — going for that flight ticket money ✈️ $PTLO small position — chasing my food money 🍔 $VTRS — for the junk food aftermath treatment money 💊

0 · Reply

ItsCarRamRod Sep. 23 at 4:46 PM

$VTRS the past 5 pullbacks have been between 30-45% applying that to this drop would put the share price between $6 to $7 dollars.

2 · Reply

Market Cap	11.79B
Revenue (ttm)	14.74B
Net Income (ttm)	-634.20M
EPS (ttm)	N/A
PE Ratio	4.19
Forward PE	4.42
Profit Margin	-4.30%
Debt to Equity Ratio	1.05

Volume	7,009,600
Avg Vol	9,895,252
Day's Range	N/A - N/A
Shares Out	1.17B
Stochastic %K	90%
Beta	0.90
Analysts	Sell
Price Target	$11.46